// STATE LEGISLATION TRACKER

Rhode Island HB 7923: AN ACT RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Rhode Island
Bill: HB 7923
Session: 2026
Filed: 2026-02-27
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Rhode Island HB7923 updates the state's controlled-substances law, mainly around opioid prescribing, pain treatment, PDMP checks, and clinician recordkeeping. It does not appear to regulate compounded peptides, off-label peptide prescribing, telehealth peptide care, naturopathic scope, NP scope, or FDA 503A/503B compounding.

Key Points

No direct change to access to compounded peptides.
No apparent change to off-label peptide prescribing rules.
No new peptide-specific telehealth restriction is indicated.
Controlled-substance prescribing stays tied to PDMP checks and records.
Opioid pain rules move away from fixed dose limits toward clinical judgment.

What to Watch For

Note Peptide clinics that also prescribe controlled substances should track Rhode Island PDMP and recordkeeping rules.

Note The bill is about controlled substances, not general prescription drugs or compounded non-controlled peptides.

✓

Opportunity Removing fixed opioid dose limits may give pain clinicians more room to use individualized judgment.

Where the Bill Stands

The bill was signed by the Governor on June 23, 2026, so it completed the legislative process.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws